Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Eiichiro Ishikawa"'
Autor:
Tomoyuki Nishimoto, Hitomi Hamajyo, Hisashi Anayama, Masao Hirakata, Eiichiro Ishikawa, Ryuichi Tozawa, Hirofumi Nagai
Publikováno v:
Toxicology and Applied Pharmacology. 223:39-45
High-dose statin treatment has been recommended as a primary strategy for aggressive reduction of LDL cholesterol levels and protection against coronary artery disease. The effectiveness of high-dose statins may be limited by their potential for myot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea60fdb34c80b3af693a94a5bb749db2
https://doi.org/10.1016/j.taap.2007.05.005
https://doi.org/10.1016/j.taap.2007.05.005
Autor:
Ryuichi Tozawa, Eiichiro Ishikawa, Yoshimi Imura, Hidefumi Yukimasa, Yasuo Sugiyama, Yuichiro Amano, Tomoyuki Nishimoto
Publikováno v:
British Journal of Pharmacology. 139:911-918
1. Squalene synthase is the enzyme that converts farnesyl pyrophosphate to squalene in the cholesterol biosynthesis pathway. We examined the lipid-lowering properties of 1-[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bca500c5eaed8ecac54042aa4ea4c5df
https://doi.org/10.1038/sj.bjp.0705332
https://doi.org/10.1038/sj.bjp.0705332
Autor:
Masayuki Ohta, Yoshimasa Ishimura, Eiichiro Ishikawa, Yoshimi Imura, Yasuo Sugiyama, Yumiko Shibouta, Takanori Matsuo
Publikováno v:
Japanese Journal of Pharmacology. 88:300-306
Spontaneously hypercholesterolemic (SHC) rats exhibit hypercholesterolemia, proteinuria and focal glomerulosclerosis with age, and they finally die as a result of renal failure. In this study, the renoprotective effects of candesartan cilexetil, an a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45387493c1222202d0d14f0639b83a1e
https://doi.org/10.1254/jjp.88.300
https://doi.org/10.1254/jjp.88.300
Autor:
Mitsuyuki Shimada, Shotaro Miura, Eiichiro Ishikawa, Emiko Shinozawa, Ryuichi Tozawa, Ryutaro Adachi, Yuichiro Amano
Publikováno v:
Life sciences. 108(1)
Aims We previously reported anti-dyslipidemic effects of a farnesoid X receptor antagonist in monkeys. In this study, we compared the cholesterol-lowering effects of single and combined administration of a farnesoid X receptor antagonist, compound-T8
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c30f7dce77ebffc53670be9d44967d4
https://pubmed.ncbi.nlm.nih.gov/24805868
https://pubmed.ncbi.nlm.nih.gov/24805868
Autor:
Hitoshi Ikeda, Nanami Miki, Hiroyuki Odaka, Hiroyuki Tawada, Eiichiro Ishikawa, Yasuo Sugiyama
Publikováno v:
Atherosclerosis. 113:71-78
Effects of TMP-153, N -[4-(2-chlorophenyl)-6,7-dimethyl-3-quinolyl]- N ′-(2,4-difluorophenyl)urea, on intestinal and hepatic acyl-CoA:cholesterol acyltransferase (ACAT) activities, cholesterol absorption and plasma cholesterol level in rats and ham
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ff2e55d9fba1f338afaeecaaa11bc82
https://doi.org/10.1016/0021-9150(94)05429-m
https://doi.org/10.1016/0021-9150(94)05429-m
Autor:
Hiroyuki Tawada, Noriaki Kawamura, Hitoshi Ikeda, Masahiro Kajino, Eiichiro Ishikawa, Kanji Meguro, Yasuo Sugiyama, Myles Harcourt
Publikováno v:
Journal of Medicinal Chemistry. 37:2079-2084
A series of 3-quinolylurea derivatives (1) was synthesized and evaluated for acyl-CoA:cholesterol acyltransferase (ACAT) inhibitory activity. For in vitro studies, the most potent inhibitory activity was found in derivatives having substituents at th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b50c6ee7e46ee985c9ef6fd34b1757f5
https://doi.org/10.1021/jm00039a020
https://doi.org/10.1021/jm00039a020
Autor:
Kanji Meguro, Hitoshi Ikeda, Hiroyuki Tawada, M. Harcourt, Noriaki Kawamura, Eiichiro Ishikawa, Y. Sugiyama, Masahiro Kajino
Publikováno v:
ChemInform. 25
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3fba898a18fb3a2b457a8c1c6e5a9832
https://doi.org/10.1002/chin.199450154
https://doi.org/10.1002/chin.199450154
Autor:
Hiroyuki Tawada, Kanji Meguro, Yasuo Sugiyama, Hideaki Natsugari, Eiichiro Ishikawa, Hitoshi Ikeda
Publikováno v:
ChemInform. 26
Novel 3-ureido derivatives of 4-phenylcoumarin and 4-phenyl-2-quinolone were synthesized and evaluated for acyl-CoA : cholesterol acyltransferase (ACAT)-inhibitory activity. These derivatives inhibited rat intestinal ACAT with IC50 values at the 10-8
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73c5e9ffe93d6f7da32ac64ccb444530
https://doi.org/10.1002/chin.199545171
https://doi.org/10.1002/chin.199545171
Autor:
Tomoyuki, Nishimoto, Yuichiro, Amano, Ryuichi, Tozawa, Eiichiro, Ishikawa, Yoshimi, Imura, Hidefumi, Yukimasa, Yasuo, Sugiyama
Publikováno v:
British journal of pharmacology. 139(5)
1. Squalene synthase is the enzyme that converts farnesyl pyrophosphate to squalene in the cholesterol biosynthesis pathway. We examined the lipid-lowering properties of 1-[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3bf926629d3e05a6ac4cddb6b4137ef2
https://pubmed.ncbi.nlm.nih.gov/12839859
https://pubmed.ncbi.nlm.nih.gov/12839859
Autor:
Ryu ichi Tozawa, Eiichiro Ishikawa, Tomoyuki Nishimoto, Yuichiro Amano, Yasuo Sugiyama, Yoshimi Imura
Publikováno v:
European journal of pharmacology. 466(1-2)
The lipid-lowering effects of 1-{2-[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-1,2,3,5-tetrahydro-2-oxo-5-(2,3-dimethoxyphenyl)-4,1-benzoxazepine-3-yl] acetyl} piperidin-4-acetic acid (TAK-475), a novel squalene synthase inhibitor, were examin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8dd5f31dbc3f082f1cd89a169a17efe3
https://pubmed.ncbi.nlm.nih.gov/12679152
https://pubmed.ncbi.nlm.nih.gov/12679152